Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Lyophilization Deficiencies topic
No spam. Unsubscribe anytime.
FDA identifies recurring lyophilization deficiencies in drug applications
Summary
In a CDER presentation, Commander Steve Ryu said common application problems include inadequate formulation characterization, poor cycle development, cake collapse, and missing scale‑up data — all issues regulators frequently see and can be prevented with proper upfront work.
Commander Steve Ryu told attendees that lyophilization is a small but high-risk part of many applications, and that "the most frequent, process related deficiencies we encounter actually come from lyophilization." He listed recurring problems: inadequate formulation-specific characterization, poorly developed cycles copied from other products, cake collapse signaling uncontrolled drying, and missing scale-up justification from development to commercial manufacturing.
Ryu warned these problems are often preventable with appropriate upfront work, including data to show how a formulation behaves during freezing and drying, well‑designed and optimized cycles for freezing, primary drying and secondary drying, and objective endpoint determination. He emphasized that lack of scale-up data can undermine submissions and complicate inspectional review.
